STOCK TITAN

Vivos Therapeutics Inc - VVOS STOCK NEWS

Welcome to our dedicated page for Vivos Therapeutics news (Ticker: VVOS), a resource for investors and traders seeking the latest updates and insights on Vivos Therapeutics stock.

Overview

Vivos Therapeutics Inc is a specialized medical technology company dedicated to addressing sleep disordered breathing (SDB) with a focus on mild-to-moderate obstructive sleep apnea (OSA). Leveraging industry-specific technology and customized oral appliance therapy, the company offers a non-surgical, non-invasive, and low-cost solution that distinguishes it within the competitive landscape of sleep health and medical devices. Key industry terms such as "obstructive sleep apnea", "sleep disordered breathing", and "oral appliance therapy" underscore its commitment to innovative clinical solutions.

Business Model and Operations

The company operates through two core revenue streams. One stream involves the development, commercialization, and direct distribution of customized oral appliances that integrate proprietary clinical protocols. These protocols, often administered by specially trained dentists in collaboration with other healthcare professionals, provide an alternative therapy to traditional CPAP treatments. The second stream is driven by the company’s licensing of its intellectual property, allowing third-party manufacturers to produce therapeutic devices according to the specialized Vivos System guidelines.

Clinical Protocols and Healthcare Integration

At the heart of Vivos Therapeutics is its Vivos System, a treatment protocol that combines device customization with targeted clinical methodologies. Through its integrated healthcare network, the company connects general dentists, medical doctors, myofunctional therapists, and chiropractors, creating a collaborative ecosystem focused on treating SDB. This structure not only facilitates patient access to specialized care but also supports the standardization of care practices within the field of sleep medicine.

Innovation and Industry Positioning

Vivos Therapeutics distinguishes itself by emphasizing non-surgical and non-pharmaceutical approaches to managing OSA. Its focus on low-cost, patient-centric treatment solutions aims to enhance accessibility and compliance, contributing to its competitive positioning against conventional therapies such as CPAP devices. The company’s ongoing efforts to refine its treatment methodologies and expand its integrated network underscore its commitment to clinical excellence and technological advancement.

Research and Development Focus

Innovation remains central to Vivos Therapeutics' strategy. The development of customizable treatment protocols and proprietary oral appliances represents a blend of technical expertise and clinical insight. The company’s research and development efforts not only drive its product offerings forward but also position it as a key contributor within the sleep health arena. By collaborating with clinical experts and leveraging insights from real-world healthcare practices, Vivos continually refines its approach to meet evolving patient needs.

Market and Competitive Landscape

Operating within the broader medical device industry, Vivos Therapeutics faces the dual challenge of technological advancement and regulatory compliance. Its focus on offering a tangible alternative to surgical and pharmaceutical interventions sets it apart. Competitors may include traditional CPAP providers and other oral appliance manufacturers; however, Vivos’ integrated clinical protocols and licensing model offer a unique value proposition that enhances its industry credibility. The company’s strategy to work closely with an array of healthcare providers also reinforces its role as a pivotal player in specialized sleep disorder treatment.

Conclusion

In summary, Vivos Therapeutics Inc provides a distinct approach to managing mild-to-moderate OSA through the use of custom oral appliances and an integrated treatment protocol. Its operations, characterized by dual revenue pathways and a comprehensive healthcare network, illustrate a robust business model suited for the evolving landscape of sleep medicine. This detailed look at its operations, innovation practices, and market positioning provides investors and industry observers with a clear understanding of its core competencies and strategic framework.

Rhea-AI Summary
Vivos Therapeutics, Inc. announces the immediate exercise of a common stock purchase warrant by an institutional investor, resulting in gross proceeds of approximately $4.0 million. The investor will purchase 980,393 shares of Vivos common stock at a revised exercise price of $4.02 per share. In return, Vivos will issue two new unregistered warrants to the investor, each allowing the purchase of 735,296 shares at an exercise price of $5.05 per share. The transaction is expected to close by February 20, 2024, with net proceeds intended for general corporate purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.14%
Tags
none
-
Rhea-AI Summary
Vivos Therapeutics, Inc. (VVOS) highlights favorable market developments, including United Healthcare's updated medical policy and recent recalls of CPAP devices by ResMed and Philips Respironics, creating significant revenue opportunities for the company's oral appliance therapies. The FDA granted a 510(k) clearance to Vivos CARE appliances to treat moderate and severe OSA in adults. Vivos is well-positioned to assist patients and providers affected by the discontinuation of CPAP devices by Philips Respironics, offering a safe and effective alternative treatment option. United Healthcare's revised OSA medical treatment policy further supports the use of oral appliance therapy, providing a substantial opportunity for Vivos to expand its user base.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.87%
Tags
none
-
Rhea-AI Summary
Vivos Therapeutics, Inc. (NASDAQ:VVOS) announced a significant increase in new dentist inquiries, VIP enrollment contracts, and CARE oral medical device orders following the FDA clearance of its oral medical devices to treat severe obstructive sleep apnea (OSA). The company reported a 600% rise in new dentist inquiries, 38% sequential increase in signed VIP enrollment contracts, and a 26% increase in CARE appliance orders. Vivos expects these positive metrics to drive revenue growth in 2024, with a 53% increase in sales of pediatric guided growth and development appliances. Toothpillow, a key dental service organization partner, also experienced a surge in interest and new patient inquiries, indicating a growing market for Vivos products.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.29%
Tags
Rhea-AI Summary
Vivos Therapeutics, Inc. (VVOS) has received FDA 510(k) clearance for its oral device to treat severe OSA, leading to the 'Empowering Women to Champion Airway' event to unite influential women in medicine and dentistry. The event aims to foster collaboration and empower women to drive positive transformations in healthcare. Vivos' CARE appliances have been granted FDA clearance to treat moderate and severe OSA in adults, providing a new alternative to CPAP or surgery. The company is hosting a conference to enhance collaboration between medical and dental professionals to provide optimal treatment solutions for patients with sleep and breathing disorders.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-14.44%
Tags
none
-
Rhea-AI Summary
Vivos Therapeutics, Inc. (NASDAQ: VVOS) has received FDA clearance for treating severe obstructive sleep apnea (OSA) in adults using the Vivos' removable CARE oral appliances, marking the first time the FDA has approved an oral appliance to treat moderate and severe OSA in adults. The statistically significant data submitted to the FDA from 73 severe OSA patients showed that 80% of patients experienced an improvement of at least 1 classification or at least a 50% improvement in the Apnea Hypopnea Index (AHI), and 97% of patients improved or stayed the same, with an average treatment time of just 9.7 months. The company believes this unprecedented decision by the FDA will generate broader acceptance throughout the medical community for Vivos treatment options, leading to the potential for higher patient referrals and case starts as well as collaboration with medical professionals, enhancing their value proposition to third-party distribution partners such as durable medical equipment (DME) companies, and clearing the way for greater reimbursement levels from medical insurance payors and Medicare, favorably impacting their ability to grow revenues in 2024 and beyond.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
833.94%
Tags
-
Rhea-AI Summary
Vivos Therapeutics, Inc. (NASDAQ: VVOS) reported a 32% year-over-year decrease in operating expenses and a 19% sequential decrease. New strategic relationships, including a U.S. nationwide distribution agreement with Lincare, are expected to bring significant new revenue opportunities. The company's cost-cutting measures have led to a 61% reduction in net loss for the third quarter of 2023, and a 47% reduction for the nine months ended September 30, 2023. Vivos also completed a private placement for net proceeds of approximately $3.5 million in November 2023 to augment its liquidity position.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.22%
Tags
Rhea-AI Summary
Vivos Therapeutics, Inc. (NASDAQ: VVOS) plans to release its third quarter 2023 financial results after market close on November 14, 2023. The company will conduct a conference call at 5:00 p.m. (Eastern Time) the same day to review the results and provide an overview of recent milestones and developments. Investors can access the conference call via phone or webcast.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.84%
Tags
-
Rhea-AI Summary
Vivos Therapeutics, Inc. has closed a $4 million private placement, with net proceeds of approximately $3.5 million. The company plans to use the funds for general working capital. In the private placement, Vivos issued 980,393 shares of common stock at a purchase price of $4.08 per share. They also issued a Series A Warrant and a Series B Warrant to purchase additional shares. A.G.P./Alliance Global Partners acted as the sole placement agent for the offering.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.52%
Tags
none
-
Rhea-AI Summary
Vivos Therapeutics, Inc. has entered into a securities purchase agreement with an institutional investor for the purchase and sale of 980,393 shares of its common stock at a price of $4.08 per share. Additionally, the investor will receive a five-year Series A Warrant and an eighteen-month Series B Warrant to purchase additional shares of common stock.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-16.19%
Tags
none
Rhea-AI Summary
Vivos Therapeutics, Inc. will undergo a 1-for-25 reverse stock split of its common stock, effective October 27, 2023. The reverse stock split aims to bring Vivos into compliance with the minimum bid price requirement for maintaining its listing on the Nasdaq Capital Market. The number of outstanding shares will be reduced from 29,928,786 shares to approximately 1,197,151 shares. Shareholders with fractional shares will have them rounded up to the nearest whole share. The exercise prices of outstanding options and warrants will be adjusted accordingly. Vivos' transfer agent, VStock Transfer LLC, will handle the exchange process for stockholders.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.83%
Tags
none

FAQ

What is the current stock price of Vivos Therapeutics (VVOS)?

The current stock price of Vivos Therapeutics (VVOS) is $2.08 as of April 16, 2025.

What is the market cap of Vivos Therapeutics (VVOS)?

The market cap of Vivos Therapeutics (VVOS) is approximately 12.7M.

What is the core focus of Vivos Therapeutics Inc?

Vivos Therapeutics Inc specializes in developing non-invasive treatments for sleep disordered breathing, particularly mild-to-moderate obstructive sleep apnea, through customized oral appliance therapy.

How does the company generate its revenue?

The company generates revenue through two main streams: direct commercialization of its proprietary oral appliance and treatment protocols, and licensing its intellectual property to third-party manufacturers.

What is the Vivos System?

The Vivos System is a proprietary treatment protocol that integrates customized oral appliances with clinical treatment methodologies, administered by specially trained healthcare professionals.

Who are the primary beneficiaries of Vivos Therapeutics' services?

The company serves a diverse range of healthcare providers including general dentists, medical doctors, myofunctional therapists, and chiropractors who administer its non-surgical, patient-centric care solutions.

What distinguishes Vivos Therapeutics from traditional CPAP therapies?

Unlike traditional CPAP therapies, Vivos Therapeutics offers a non-surgical and non-pharmaceutical alternative that emphasizes ease of use and patient compliance through custom-designed oral appliances.

How does Vivos Therapeutics integrate with the healthcare ecosystem?

The company operates an integrated healthcare network that facilitates collaboration among various specialists to ensure that patients receive standardized and effective treatment for sleep disordered breathing.

What market challenges does Vivos Therapeutics face?

Key challenges include navigating regulatory frameworks, maintaining technological innovation against competitors, and ensuring widespread adoption of its non-invasive treatment solutions in a market traditionally dominated by CPAP manufacturers.

How does Vivos Therapeutics demonstrate industry expertise?

The company demonstrates expertise by employing detailed clinical protocols, engaging in continuous research and development, and collaborating with a broad range of healthcare professionals to refine its treatment system.
Vivos Therapeutics Inc

Nasdaq:VVOS

VVOS Rankings

VVOS Stock Data

12.66M
5.42M
8%
13.7%
5.84%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States
LITTLETON